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A B S T R A C T 
Introduction: Catheter-associated urinary tract 
infection is a major hospital-acquired infection. This 
study aimed to analyse the effect of a silver alloy 
and hydrogel−coated catheter on the occurrence of 
catheter-associated urinary tract infection.
Methods: This was a 1-year prospective study 
conducted at a single centre in Hong Kong. Adult 
patients with an indwelling urinary catheter for 
longer than 24 hours were recruited. The incidence 
of catheter-associated urinary tract infection in 
patients with a conventional latex Foley catheter 
without hydrogel was compared with that in patients 
with a silver alloy and hydrogel−coated catheter. The 
most recent definition of urinary tract infection was 
based on the latest surveillance definition of the 
National Healthcare Safety Network managed by 
Centers for Disease Control and Prevention.
Results: A total of 306 patients were recruited with 
a similar ratio between males and females. The 
mean (standard deviation) age was 81.1 (10.5) years. 
The total numbers of catheter-days were 4352 and 
7474 in the silver-coated and conventional groups, 
respectively. The incidences of catheter-associated 
urinary tract infection per 1000 catheter-days were 
6.4 and 9.4, respectively (P=0.095). There was a 31% 
reduction in the incidence of catheter-associated 
urinary tract infection per 1000 catheter-days in the 
silver-coated group. Escherichia coli was the most 
commonly involved pathogen (36.7%) of all cases. 
Subgroup analysis revealed that the protective effect 
of silver-coated catheter was more pronounced 
in long-term users as well as female patients with 
A prospective interventional study to examine 
the effect of a silver alloy and hydrogel−coated 
catheter on the incidence of catheter-associated 
urinary tract infection
Introduction
Catheter-associated urinary tract infection (CA-
New knowledge added by this study
• The use of a silver alloy and hydrogel−coated (SAH) catheter has the potential to reduce catheter-associated 
urinary tract infection (CA-UTI), especially in certain subgroups of patients (long-term users and female 
patients).  
Implications for clinical practice or policy
• The use of a SAH catheter potentially reduces the incidence of CA-UTI. This will lead to less morbidity and 
medical costs associated with CA-UTI. 
• This study provides pilot data for future research.
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UTI) is a major cause of hospital-acquired infection, 
with local data showing 4.9 infections per 1000 
ORIGINAL ARTICLE
a respective 48% (P=0.027) and 42% (P=0.108) 
reduction in incidence of catheter-associated 
urinary tract infection. The mean catheterisation 
time per person was the longest in patients using 
a silver-coated catheter (17.0 days) compared with 
those using a conventional (10.8 days) or both types 
of catheter (13.6 days) [P=0.01]. 
Conclusions: Silver alloy and hydrogel−coated 
catheters appear to be effective in preventing 
catheter-associated urinary tract infection based 
on the latest surveillance definition. The effect is 
perhaps more prominent in long-term users and 
female patients.
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一項前瞻性介入研究以探討銀合金水凝膠塗層導
管對出現導管相關性尿道感染的影響
鍾浩宇、黃詠欣、賴貫之、邵漢基、曾艾壯、楊健玉、 
葉啟明、譚廣亨
引言：導管相關性尿道感染是醫院內感染中最常見的一種。本研究旨
在分析銀合金水凝膠塗層導管對出現導管相關性尿道感染的影響。
方法：這前瞻性研究在香港一個單一中心內進行，為期一年。研究對
象為使用留置導尿管超過24小時的成年病人。並將使用銀合金水凝膠
塗層導管的病人和使用傳統沒有水凝膠的Foley（乳膠）導管的病人進
行比較，找出兩組導管相關性尿道感染的發生率。病人是否有尿道感
染是按美國疾病管制中心成立的國家健康照護安全網絡的最新定義來
判斷。
結果：共306名病人參與本研究，他們平均年齡（標準差）為81.1
（10.5）歲，男女比例相若。銀合金水凝膠塗層導管和傳統Foley導管
兩組的導管使用人日分別為4352天和7474天，而每一千導管人日的導
管相關性尿道感染發生率分別為6.4和9.4（P=0.095）。銀合金水凝膠
塗層導管組別的每一千導管人日的導管相關性尿道感染下降了31%。
大腸桿菌是所有病人中最常見的病原體（36.7%）。亞組分析顯示銀
合金水凝膠塗層導管的保護作用在長期使用者以及女性病人當中更加
明顯，前者的導管相關性尿道感染發生率減少了48%（P=0.027），後
者減少了42%（P=0.108）。留置導管的時間方面，使用銀合金水凝膠
塗層導管的病人為最長（平均17.0天），使用傳統Foley導管的病人為
10.8天，曾使用兩種導管的則為13.6天（P=0.01）。
結論：根據對尿道感染的最新監測定義，銀合金水凝膠塗層導管似乎
能有效預防導管相關性尿道感染。此效應在長期使用者和女性病人當
中可能更明顯。
catheter-days.1 Internationally, an estimated 900 000 
nosocomial UTIs occur every year, prolonging the 
mean duration of hospital stay by 1 to 3.8 days. It 
has been estimated that approximately 80% of UTIs 
are related to the presence of an indwelling urinary 
catheter. In severe cases, these infections may lead 
to bacteraemia, urosepsis, and even mortality.2,3 A 
case-control study also suggested that patients with 
CA-UTI had excess costs of US$3803 compared with 
patients without infection.4 Therefore, by prevention 
of CA-UTI, a significant reduction in morbidity 
and mortality, as well as the health care economic 
burden, can be anticipated. 
 Bactiguard-coated Foley catheters (Bactiguard, 
Sweden) were approved by the US Food and Drug 
Administration in 1994. These catheters have a stable 
noble metal alloy and hydrogel coating (also referred 
to as silver alloy and hydrogel−coated, SAH) on the 
outer- and inner-luminal surfaces of the catheter, 
providing repellent and anti-infective properties by 
preventing the formation of microbial biofilm. The 
coating consists of gold, silver and palladium, and 
also preserves the urethral mucosal integrity and 
helps to avoid the onset of inflammation. Previous 
studies of CA-UTI prevention had asymptomatic 
bacteriuria (ASB) alone or in combination with 
symptomatic UTI as the endpoint so their clinical 
relevance was called into question. We conducted 
a prospective, interventional study to provide 
additional data on the effectiveness of the noble 
metal alloy urinary catheter in the prevention of 
CA-UTI, using the updated surveillance definition 
of National Healthcare Safety Network (NHSN) 
managed by the Centers for Disease Control and 
Prevention (CDC). This surveillance definition 
was adopted in 2009 and modified the criteria for 
symptomatic infection, as well as adding a category 
and definition for asymptomatic bacteraemic UTI 
together with the removal of ASB completely.5 To 
study the effect on ASB, we adopted the criteria 
used in the Infectious Diseases Society of America 
practice guideline developed in 2009.6
Methods
This single-centre 1-year prospective study was 
completed in 2012 in a regional rehabilitation 
hospital in Hong Kong. The study population was 
in-patients in two medical rehabilitation wards. All 
patients over 18 years of age on either of the wards 
during the study period with an indwelling catheter 
for longer than 24 hours were recruited after 
giving informed consent. Patients who underwent 
suprapubic catheterisation, single in-and-out 
catheterisation for collection of a urine specimen, 
intermittent catheterisation for urine drainage, 
catheterisation for less than 24 hours, or who were 
catheterised with a silicone Foley catheter, and those 
who had been treated with antibiotics for a UTI were 
excluded from the study. Both of the study wards 
rotated through the two different interventions in 
two 6-month periods in order to act as a self-control 
to minimise the potential problem of variability 
in medical and nursing practice that might affect 
the outcomes. Conventional latex Foley catheters 
without hydrogel (sized Fr 12, 14, and 16) were used 
for catheterisation on both wards during the first 
half of the study period; SAH catheters (sized Fr 
12, 14, and 16) were used during the second half of 
the study period. If a catheter was changed due to 
the presence of infection, the appropriate catheter 
according to the month of the study was used. Thus 
it was possible for patients who required a catheter 
for a long time and underwent catheter exchange to 
be exposed to both types of urinary catheter (Fig 1). 
 The definition of CA-UTI was adopted 
and modified from the CDC/NHSN definition of 
symptomatic UTI (Appendix5,6). Routine, regular 
screening and clinical urine samples were collected 
from all subjects according to the hospital protocol. 
Routine urine samples were taken from all subjects 
at four fixed time-points: on admission, on 
catheterisation, before removal of the catheter, and 
before hospital discharge. Screening samples were 
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taken weekly. Clinical samples were taken whenever 
a patient demonstrated symptoms and signs of 
UTI, or as part of a sepsis workup. The incidence 
of CA-UTI in the two groups was analysed in terms 
of the absolute number of CA-UTI episodes and 
the number of CA-UTI episodes per 1000 catheter-
days. Values were expressed as mean ± standard 
deviation. Comparison between the two groups was 
performed by Pearson’s Chi squared test, Student’s 
t test, and one-way analysis of variance test when 
appropriate with a two-sided significance level of 
0.05. The rate ratio of CA-ASB and CA-UTI between 
the two groups was compared by exact Poisson test 
for rate ratio. The occurrence of CA-UTI between 
the two groups was also analysed with Kaplan-Meier 
analysis. Results were analysed using the Statistical 
Package for the Social Sciences (Windows version 
21.0; SPSS Inc, Armonk [NY], US) and R version 
3.1.2. 
 This study was done in accordance with the 
principles outlined in the Declaration of Helsinki.
Results
During the 1-year study period, 306 patients were 
recruited. The male-to-female ratio was 1:1.13 and 
the mean age was 81.1 ± 10.5 years (Table 1). Overall, 
187 patients used a conventional catheter only, 36 
patients used a SAH catheter only, and 83 patients 
used both a conventional and a SAH catheter (Fig 1). 
 The total numbers of catheter-days were 4352 
and 7474 in the SAH and conventional groups, 
respectively. The numbers of CA-UTI episodes 
were 28 and 70, respectively. Thus the incidences 
of CA-UTI per 1000 catheter-days in the SAH and 
conventional groups were 6.4 and 9.4, respectively 
(P=0.095) with a rate ratio of 0.69 (95% confidence 
interval [CI], 0.42-1.08). There was a 31% reduction in 
FIG 1.  Flowchart showing the study design and patient distribution
* The Bactiguard Infection Protection Foley Catheter
6 Months 6 Months
187 Patients
Parallel
subgroup
Cross-over
subgroup
36 Patients
83 Patients
Conventional Foley
374 Catheters, 10.8 days/catheter
Conventional Foley
371 Catheters, 9.3 days/catheter
BIP Foley*
65 Catheters, 17.0 days/catheter
BIP Foley*
67 Catheters, 48 days/catheter
TABLE 1.  Characteristics of the study population, specimens collected, and catheter used
Characteristic Mean ± standard deviation Independent t test (female vs male)
All patients 
(n=306)
Female patients 
(n=162)
Male patients 
(n=144)
P value Mean difference (95% 
confidence interval)
Age	(years) 81.1	±	10.5 82.6	±	10.3 79.5	±	10.5 0.01 3.1	(0.7	to	5.4)
No.	of	specimens	collected	
Screening 7.6	±	13.9 7.6	±	13.0 7.5	±	14.9 0.95 0.1	(-3.0	to	3.2)
Clinical 0.4	±	0.7 0.4	±	0.7 0.4	±	0.8 0.98 0.0	(-0.2	to	0.2)
No.	of	catheters	used	
Silver	alloy	and	hydrogel−coated	 0.8	±	1.5 0.8	±	1.5 0.7	±	1.5 0.44 0.1	(-0.2	to	0.5)
Conventional 2.2	±	2.6 2.1	±	2.6 2.2	±	2.8 0.81 -0.1	(-0.7	to	0.5)
All	catheters 2.9	±	3.5 3.0	±	3.4 2.9	±	3.7 0.88 0.1	(-0.7	to	0.9)
No.	of	catheter-days	
Silver	alloy	and	hydrogel−coated	 14.2	±	35.3 14.7	±	34.2 13.7	±	36.6 0.79 1.1	(-6.9	to	9.0)
Conventional 24.4	±	33.4 24.4	±	33.0 24.5	±	33.9 0.97 -0.2	(-7.7	to	7.4)
All	catheters 38.6	±	59.8 39.1	±	57.2 38.2	±	62.9 0.89 0.9	(-12.6	to	14.4)
CA-UTI incidence in the SAH group. Using Kaplan-
Meier analysis and log-rank test, SAH catheter was 
associated with a significantly lower rate of CA-UTI 
(P=0.045; Fig 2). Regarding CA-ASB, the incidences 
per 1000 catheter-days in the SAH and conventional 
groups were 70.8 and 67.2, respectively (P=0.467) 
with a rate ratio of 1.05 (95% CI, 0.91-1.22). Results 
are summarised in Table 2. Blood cultures were 
taken from patients who developed CA-UTI. In both 
groups, none of the patients with CA-UTI developed 
bacteraemia. Escherichia coli was the most commonly 
involved urinary pathogen and accounted for 36.7% 
of all cases, followed by Candida albicans (17.3%) 
and Proteus mirabilis (14.3%) [Table 3]. The same 
pathogens were observed in both groups. 
 This study was not a randomised controlled 
trial. Thus to eliminate patient selection bias, a 
subgroup analysis was performed among those 
patients who used both types of catheter (n=83). 
These patients had more catheters used and more 
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catheter-days than those patients who used only one 
type of catheter (Table 4a). This was due to study 
design where longer-term users had a higher chance 
of exposure to both types of urinary catheter. Among 
them, the total numbers of catheter-days were 3210 
and 3457 in the SAH and conventional groups, 
respectively. The numbers of CA-UTI episodes 
were 17 and 35, respectively. This resulted in the 
incidences of CA-UTI per 1000 catheter-days in the 
SAH and conventional groups being 5.3 and 10.1, 
respectively (P=0.027) with a rate ratio of 0.52 (95% 
CI, 0.27-0.96). There was a statistically significant 
reduction of 48% in CA-UTI incidence in the 
SAH group (Table 4b). Because the catheters were 
exchanged when an infection occurred, the CA-UTI 
reducing effect resulted in less need to exchange a 
SAH catheter—the mean catheterisation time per 
person was 17.0 days for a SAH catheter compared 
with 10.8 days for a conventional catheter and 13.6 
days for patients using both catheters (Table 4a). 
 To examine the presence of outcome difference 
in relation to gender in the entire study population, 
we also performed a subgroup analysis based on 
gender differences (Table 4c). In male patients 
(n=144), the number of CA-UTI episodes was 15 in 
the SAH group (total catheter-days, 1966) and 33 in 
the conventional group (total catheter-days, 3529). 
The incidences of CA-UTI per 1000 catheter-days 
in the SAH and conventional groups were 7.6 and 
9.4, respectively (P=0.551) with a rate ratio of 0.82 
(95% CI, 0.41-1.54). For female patients (n=162), 
the number of CA-UTI episodes was 13 in the 
SAH group (total catheter-days, 2386) and 37 in the 
conventional group (total catheter-days, 3945). The 
incidences of CA-UTI per 1000 catheter-days in 
the SAH and conventional groups were 5.4 and 9.4, 
respectively (P=0.108), with a rate ratio of 0.58 (95% 
CI, 0.28-1.12).
Discussion
Urinary tract infection is one of the most commonly 
encountered infections in daily clinical practice and 
the majority of cases are catheter-related. Although 
a number of clinical practices such as aseptic 
technique for catheter insertion, closed drainage 
systems, and shorter duration of catheterisation have 
been introduced in an attempt to reduce the onset of 
CA-UTI, the incidence remains high.3,7 Therefore, 
research for strategies or new technologies to 
prevent CA-UTI is still needed. Since the early 
1990s, research has focused on different anti-
infective catheter-coating materials but results have 
FIG 2.  Comparison of CA-UTI occurrence between SAH and conventional 
catheters in the entire study population using Kaplan-Meier analysis
Abbreviations: CA-UTI = catheter-associated urinary tract infection; SAH = silver alloy 
and hydrogel−coated
100
80
60
40
20
0
%
No. of catheter-days
403020100
Type of catheter
SAH catheter
Conventional catheter
SAH catheter–censored
Conventional catheter–censored
TABLE 2.  Overall comparison of CA-UTI and CA-ASB episodes between SAH catheters and conventional catheters
Variable SAH group 
(a)
Conventional group 
(b)
Rate ratio a/b (95% 
confidence interval)
P value (exact Poisson 
test for rate ratio)
No. of patients 119 270 - -
No.	of	catheters 159 635 - -
No.	of	catheter-days 4352	 7474	 - -
CA-ASB	episodes 308	 502	 - -
CA-ASB	episodes/1000	catheter-days 70.8 67.2 1.05	(0.91-1.22) 0.467
CA-UTI	episodes 28	 70 - -
CA-UTI	episodes/1000	catheter-days 6.4 9.4 0.69	(0.42-1.08) 0.095
Abbreviations: CA-ASB = catheter-associated asymptomatic bacteriuria; CA-UTI = catheter-associated urinary tract infection; SAH = silver alloy and 
hydrogel−coated
P=0.045
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been generally inconclusive. Bactiguard-coated 
Foley catheters, an essential noble metal (gold, silver, 
and palladium) alloy and hydrogel–coated catheter, 
have been introduced to slow bacterial colonisation. 
 In the early 2000s, a randomised cross-over 
study by Karchmer et al8 demonstrated that the risk of 
UTI could be decreased by 21% on wards and by 32% 
among patients when a noble metal alloy catheter 
was used instead of a conventional catheter. Since 
then, more studies to compare anti-infective urinary 
catheters with conventional urinary catheters have 
been carried out. The noble metal alloy indwelling 
catheter has been shown in multiple large clinical 
trials and smaller case studies to reduce the incidence 
of CA-UTI, when compared with conventional 
catheters.9-15 These studies have examined endpoints 
such as bacteriuria and symptomatic CA-UTI, or 
surveillance-defined UTI.8,16,17 In a study by Pickard 
et al,17 noble metal alloy catheters were found to be 
ineffective in reducing the incidence of symptomatic 
surveillance-defined UTI when used in short-term 
(mean, 2 days) surgical patients and they did not 
support the routine use of these catheters in this 
patient group. Lack of effect is not surprising due to 
the short catheterisation time and low-risk patient 
group. In a more recent multicentre cohort study in 
2014, Lederer et al4 examined the impact of noble 
metal alloy catheters on symptomatic CA-UTI and 
antibiotic use based on the NHSN surveillance and 
concluded that a 58% relative reduction (P<0.0001) 
in NHSN-defined CA-UTI rate was observed and 
60% fewer antibiotics were used when compared 
with conventional catheters. 
 In the present study, we were able to 
demonstrate a 31% reduction in the incidence of 
CA-UTI episodes per 1000 catheter-days in the 
SAH group although it did not reach statistical 
significance, likely due to too small study groups. 
We believe that the incidence rate per catheter-
days is a more appropriate comparison to reflect the 
risk of infection associated with different types of 
catheter as it also takes into account the duration of 
catheterisation, which is known to be an important 
factor associated with the incidence of CA-UTI. This 
is also reflected by the fact that the noble metal alloy 
catheter can be left in situ for the longest period 
of time. Although the cost of each SAH catheter 
(approximately HK$100) is higher than that of a 
conventional catheter (approximately HK$15), we 
believe the benefit of longer duration and potential 
reduction in CA-UTI justify its use.
 With subgroup analysis, the effect of a noble 
TABLE 3.  Organisms identified from CA-UTI specimens (some specimens showed mixed flora)
Organisms SAH group Conventional group Total
Gram-negative	organisms 26 92
(All	ESBL	producers) 8 23
Enterobacteriaceae
Escherichia coli 12 24 36
(ESBL	producers) (8) (15)
Proteus mirabilis 5 9 14
(ESBL	producers) (0) (4)
Klebsiella pneumoniae	/	species 4 6 10
(ESBL	producers) (0) (1)
Other	Enterobacteriaceae 2 8 10
(ESBL	producers) (0) (3)
Pseudomonas aeruginosa	/	species 1 12 13
Acinetobacter	species 2 1 3
Gram-positive	organisms 7 11
Enterococcus	species 5 7 12
Methicillin-resistant	Staphylococcus aureus 2 3 5
Coagulase-negative	Staphylococcus 0 1 1
Fungi 5 22
Candida albicans 3 14 17
Candida	species 2 8 10
Total No. of positive samples 28 70 98
Abbreviations: CA-UTI = catheter-associated urinary tract infection; ESBL = extended spectrum beta lactamase; SAH = silver alloy 
and hydrogel−coated
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* Chi squared test
† One-way analysis of variance
TABLE 4.  (a) Characteristics of patients who used both types of catheter, SAH catheter only, or conventional catheter only. (b) Comparison of CA-UTI 
and CA-ASB incidences between SAH and conventional catheters in 83 patients who used both types of catheter (cross-over group). (c) Comparison of 
CA-UTI and CA-ASB incidences between SAH and conventional catheters in male and female patients
No. of patients or mean ± SD P value
Both types of catheter 
(n=83)
SAH catheter only 
(n=36)
Conventional catheter 
only (n=187)
Sex 0.41*
Female 49 19 94
Male 34 17 93
Diabetes	mellitus	 0.97*
Yes 17 8 38
No 66 28 149
Age	(years)	 79.2	±	12.5 82.8	±	10.2 81.7	±	9.5 0.12†
No.	of	catheters	per	patient	(all	catheters) 5.5	±	5.6 1.9	±	1.6 2.0	±	1.4 <0.001†
No.	of	catheter-days	per	patient	(all	catheters) 80.3	±	97.2 31.7	±	38.7 21.5	±	18.4 <0.001†
Average	days	per	catheter	per	person 13.6	±	4.8 17.0	±	9.8 10.8	±	4.9 0.01†
(a)
(b)
(c)
SAH catheter 
(a)
Conventional 
catheter (b)
Rate ratio a/b (95% 
confidence interval)
P value (exact Poisson 
test for rate ratio)
No.	of	catheters 67 371
No.	of	catheter-days 3210	 3457	  
No.	of	days	per	catheter 48 9.3
CA-ASB	episodes 206	 201	
CA-ASB	episodes/1000	catheter-days 64.2 58.1 1.10	(0.90-1.34) 0.322	
CA-UTI	episodes 17	 35	  
CA-UTI	episodes/1000	catheter-days 5.3 10.1 0.52	(0.27-0.96) 0.027
SAH catheter 
(a)
Conventional 
catheter (b)
Rate ratio a/b (95% 
confidence interval)
P value (exact Poisson 
test for rate ratio)
Male	patients	(n=144)
No. of patients 51 127
No.	of	catheters 98 318
No.	of	catheter-days 1966	 3529	  
CA-ASB	episodes 134	 211	
CA-ASB	episodes/1000	catheter-days 68.2 59.8 1.14	(0.91-1.42) 0.239
CA-UTI	episodes 15	 33	
CA-UTI	episodes/1000	catheter-days 7.6 9.4 0.82	(0.41-1.54) 0.551
Female	patients	(n=162)
No. of patients 68 143
No.	of	catheters 132 346
No.	of	catheter-days 2386	 3945	
CA-ASB	episodes 174	 291	
CA-ASB	episodes/1000	catheter-days 72.9 73.8 0.99	(0.81-1.20) 0.924
CA-UTI	episodes 13	 37	
CA-UTI	episodes/1000	catheter-days 5.4 9.4 0.58	(0.28-1.12) 0.108
Abbreviations: CA-ASB = catheter-associated asymptomatic bacteriuria; CA-UTI = catheter-associated urinary tract infection; SAH = silver alloy and 
hydrogel−coated; SD = standard deviation
#  Silver-alloy hydrogel-coated catheter  # 
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metal alloy catheter on reduction of CA-UTI was 
more prominent in long-term users and female 
patients. In patients who used both catheters 
and who served as their own control, a significant 
reduction (48%, P=0.027) was observed in the SAH 
group. The same reduction was not observed in 
those who used only one type of urinary catheter 
whose number of catheters used and catheter-
days were significantly fewer (Table 4a and 4b). We 
cannot give an exact explanation for this observation 
but we believe the protective effect of Bactiguard 
catheters is best seen in patients who require long-
term urinary catheterisation. Nonetheless, it must 
be emphasised that the effect due to mixed use of 
catheters is unknown. The reduction in CA-UTI 
was also slightly more prominent in female patients 
(rate ratio of CA-UTI episodes per 1000 catheter- 
days, 0.58; Table 4c). Whether these are genuine and 
significant findings will warrant future randomised 
controlled studies to confirm.
 This study has several limitations. First, this 
was a non-randomised study with a lack of blinding 
of outcome observers. Second, some patients might 
have used both catheters and the effects of each 
catheter type might have confounded the results. 
Third, as patients were recruited from a regional 
rehabilitation hospital, their underlying different 
medical conditions and risk factors might have 
affected the outcomes. As patients admitted during 
the two 6-month periods were incomparable, 
confounding by underlying risk factors for CA-UTI 
could not be excluded.
Conclusions
Our findings suggest that SAH-coated  catheters may 
be effective in reducing CA-UTI based on CDC’s 
NHSN surveillance definition. The effect seems to be 
more pronounced in high-risk patients such as long-
term users and female patients. Future randomised 
controlled studies on this subject should be carried 
out based on these pilot data.
Appendix
Additional material related to this article can be 
found on the HKMJ website. Please go to <http://
www.hkmj.org>, and search for the article.
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